The multiomics blueprint of the individual with the most extreme lifespan
Eloy Santos-Pujol(Josep Carreras Leukaemia Research Institute), Donald J. L. Jones(University of Leicester), Aleix Noguera‐Castells(Josep Carreras Leukaemia Research Institute), Claudia Vasallo(Pasqual Maragall Foundation), Xavier Aldeguer(Hospital Universitari de Girona Doctor Josep Trueta), Lauro Sumoy(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Pamela Acha(Josep Carreras Leukaemia Research Institute), Ignacio Campillo‐Marcos(Josep Carreras Leukaemia Research Institute), Carles Arribas(Josep Carreras Leukaemia Research Institute), Mar Mallo(Josep Carreras Leukaemia Research Institute), Caterina Mata(Josep Carreras Leukaemia Research Institute), Marta Casado-Peláez(Josep Carreras Leukaemia Research Institute), Óscar Yanes(Instituto de Salud Carlos III), Isabel Granada(Josep Carreras Leukaemia Research Institute), Fernando Setién(Bellvitge University Hospital), Raúl Sánchez-Vazquez(Spanish National Cancer Research Centre), Raquel Pluvinet(Josep Carreras Leukaemia Research Institute), Gerardo Ferrer(Josep Carreras Leukaemia Research Institute), Alberto Bueno-Costa(Josep Carreras Leukaemia Research Institute), Marc Llirós(Universitat de Vic - Universitat Central de Catalunya), Paula Martínez(Spanish National Cancer Research Centre), Elisabetta Mereu(University of Turin), Francisco Villavicencio(Johns Hopkins University), Sara Samino(Hospital Sant Pau i Santa Tecla), Verónica Dávalos(Josep Carreras Leukaemia Research Institute), Aleix Lluansí(Institut d'Investigació Biomèdica de Girona), Montse Guardiola(Instituto de Salud Carlos III), Robert Carreras‐Torres(Institut de Biologia Evolutiva), Marta Massip‐Salcedo(Universitat de Barcelona), Françesc Solé(Fundación Josep Carreras Contra la Leucemia), Thong Huy Cao(University of Leicester), Josep Ribalta(Instituto de Salud Carlos III), Marı́a A. Blasco(Spanish National Cancer Research Centre), L. J. Garcia‐Gil(Universitat de Girona), Carlos A. García‐Prieto(Barcelona Supercomputing Center), Eva Crespo-García(Josep Carreras Leukaemia Research Institute), Julia Rius-Bonet(Pasqual Maragall Foundation), Carlos Quero-Dotor(Josep Carreras Leukaemia Research Institute), Carolina de la Torre(Josep Carreras Leukaemia Research Institute), Paulene A. Quinn(University of Leicester), Natalie S. Coles(APLA Health), Sara Peregrina(Barcelona Supercomputing Center), Meritxell Pujolassos(Universitat de Vic - Universitat Central de Catalunya), Jose Oviedo(University of Arizona), Bernardo Lemos(University of Arizona), Marta Torrubiano(Universitat Oberta de Catalunya), Núria Amigó(Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas), Kamal A. Khidir(University of Leicester), Toni Gabaldón(Institució Catalana de Recerca i Estudis Avançats)
Cited by 15
Related Papers
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease
|Nature Communications|2023|280
Dynamics of life expectancy and life span equality
|Proceedings of the National Academy of Sciences|2020|260
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing
|Proceedings of the National Academy of Sciences|2011|255